Research Paper Volume 14, Issue 13 pp 5590—5610
A pan-cancer analysis confirms PTPN11’s potential as a prognostic and immunological biomarker
Figure 4. Phosphorylation analysis of PTPN11 protein in various cancers according to the CPTAC database. It was retrieved from the UALCAN in order to compare the phosphorylation levels of PTPN11 (NP 002825.3, S36, S562, Y546, Y584, Y542, and Y580) in several malignant tissues to that of normal tissues. (A) The phosphorylation sites of the PTPN11 protein are depicted in the diagram. The box plots are shown for several malignancies, such as (B) breast cancer, (C) HNSC, (D) clear cell RCC, and (E) LUAD.